Form 4: DENTSPLY SIRONA EVP & CFO Matthew Garth Receives Significant Equity Awards

DENTSPLY SIRONA Inc.'s Executive Vice President and Chief Financial Officer, Matthew E. Garth, was granted 43,023 Restricted Stock Units and 173,800 stock options as part of his compensation.

Summary

• Matthew E. Garth, EVP & CFO of DENTSPLY SIRONA Inc. (XRAY), acquired 43,023 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 30, 2025, at a price of $0.
• These RSUs will vest in annual one-third (1/3) increments over a three-year period, concluding on May 30, 2028.
• Additionally, Mr. Garth acquired 173,800 Stock Options (Right to Buy) on May 30, 2025, with an exercise price of $15.98.
• The stock options also vest in annual one-third (1/3) increments over a three-year period, ending on May 30, 2028, and have an expiration date of May 30, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the equity awards align executive interests with shareholders, which is generally viewed favorably for corporate governance and long-term performance incentives. However, it's a routine compensation disclosure, not indicative of new operational performance.

Positives

• The equity awards align the interests of the EVP & CFO with those of the shareholders, as the value of these awards is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and performance from the executive.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on executive equity compensation.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation in the form of equity awards, common across publicly traded companies in all industries, including the dental products and technology sector where DENTSPLY SIRONA operates. It reflects standard practices for aligning executive incentives with shareholder value.

Stakeholder Impact

• Shareholders: The equity awards align the interests of the EVP & CFO with shareholders, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The EVP & CFO receives significant equity-based compensation, incentivizing his performance and retention.

Next Steps

• The Restricted Stock Units and Stock Options will vest in one-third increments annually over the next three years, with the final vesting on May 30, 2028.

Key Dates

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Awards, Corporate Governance